Fulcrum Therapeutics (FULC) Enterprise Value (2018 - 2026)
Fulcrum Therapeutics' (FULC) quarterly Enterprise Value came in at -$50.3 million in Q1 2026, down 19.16% year-on-year from -$62.2 million in Q1 2025, and up 74.56% on a QoQ basis from -$197.5 million in Q4 2025.
Fulcrum Therapeutics (FULC) Enterprise Value (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Enterprise Value data on file, last reported at -$50.3 million in Q1 2026.
- On a quarterly basis, Enterprise Value fell 19.16% year-over-year to -$50.3 million in Q1 2026; TTM through Mar 2026 was -$50.3 million, a 19.16% decrease from a year earlier, with the FY2025 full-year figure at -$197.5 million, up 18.04% from the prior year.
- Enterprise Value for Q1 2026 stood at -$50.3 million, up from -$197.5 million in the prior quarter.
- Over the last five years, Enterprise Value for FULC reached as high as -$30.1 million in Q3 2023 and fell as low as -$241.0 million in Q4 2024.
- Historically, Enterprise Value has averaged -$89.8 million across 5 years, with a median of -$47.1 million in 2025.
- Across the five-year window, Enterprise Value soared 66.93% in 2022 and sank 573.03% in 2023, its largest moves.
- Year by year, Enterprise Value stood at -$35.1 million in 2022, then sank by 573.03% to -$236.2 million in 2023, then declined by 2.03% to -$241.0 million in 2024, then climbed by 18.04% to -$197.5 million in 2025, then soared by 74.56% to -$50.3 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$50.3 million in Q1 2026, -$197.5 million in Q4 2025, and -$47.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Fulcrum Therapeutics | 286.57 Mn | 286.57 Mn | - | -50.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.26 Mn |
| Dec 31, 2025 | -197.53 Mn |
| Sep 30, 2025 | -47.08 Mn |
| Jun 30, 2025 | -214.11 Mn |
| Mar 31, 2025 | -42.18 Mn |
| Dec 31, 2024 | -241.02 Mn |
| Sep 30, 2024 | -72.63 Mn |
| Jun 30, 2024 | -86.70 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Dec 31, 2023 | -236.22 Mn |
| Sep 30, 2023 | -30.08 Mn |
| Jun 30, 2023 | -33.97 Mn |
| Mar 31, 2023 | -34.73 Mn |
| Dec 31, 2022 | -35.10 Mn |
| Sep 30, 2022 | -90.94 Mn |
| Jun 30, 2022 | -40.15 Mn |
| Mar 31, 2022 | -33.31 Mn |
| Dec 31, 2021 | -35.41 Mn |
| Sep 30, 2021 | -65.47 Mn |
| Jun 30, 2021 | -56.78 Mn |